Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.

Trial Details

NCT ID

NCT06498154

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

Locations (sample)

Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

Female initial treatment patients aged ≥ 18 years and ≤ 70 years old
ECOG score 0-1
Clinical T1-2N0 HER2 positive ( HR negative HER2 IHC score of 3+, or 2+and ISH test positive) or triple negative invasive breast cancer
Left ventricular ejection fraction (LVEF) ≥ 50%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →